Researchers followed glucose monitor users for three years and found a possible kidney benefit - News-Medical

According to extensive coverage from outlets including News-Medical, Patient Care Online, VZ VermögensZentrum, Dexcom Investor Relations, Mirage News, Business Wire, MedPage Today, Waikato Times, KOKH, BW Healthcare World, and Pharmacy Times, continuous glucose monitoring technology is currently the subject of widespread reporting. Additional findings from the landmark Dexcom CONNECT study, published in The New England Journal of Medicine, suggest that continuous glucose monitors help type 2 patients spend five more hours in a healthy range, redefining the standard of care for this patient demographic. Media attention centers heavily on the expansion of primary care candidate pools for continuous glucose monitors, as discussed in Patient Care Online, alongside broader analyses regarding whether these tools are worth the investment for diabetes management, as featured in BW Healthcare World and Pharmacy Times. KOKH coverage notes discussions by Dr.

Anila Bindal on Living Oklahoma regarding device misconceptions and benefits, supported by Abbott. Meanwhile, regional reporting from the Waikato Times emphasizes that thousands of individuals could experience extended lifespans through the adoption of continuous glucose monitoring devices. This trend emerges against the backdrop of ongoing clinical evaluations regarding self-monitoring blood glucose tools and their role in preventing and reducing prediabetes and diabetes-related complications. Coverage highlights a shift in clinical focus toward non-insulin-treated type 2 diabetes populations, where traditional monitoring has often differed from intensive insulin management protocols.

Clinical trials such as the CONNECT study provide empirical data on glycemic control metrics, including time spent in healthy glucose ranges and reductions in A1C levels, prompting medical discussions about widening access in primary care settings. Future updates will depend on clinical follow-ups regarding the three-year kidney benefit findings and potential updates to primary care prescribing guidelines. Coverage does not yet specify exact regulatory or reimbursement shifts resulting from the New England Journal of Medicine publication, leaving open how healthcare systems internationally will integrate these monitoring devices into standard care pathways for patients managing type 2 diabetes without insulin therapy.